Pipeline of Innovative RNA Therapeutics
Multitargeting SeekR Programs
OLI-0101 Anti-Cancer SeekR Program
Multitargeting SeekR™ to trigger synthetic lethality in colon tumors
Lead Candidate: aptEpCAM + siTargetSL + aptHER3
Binders direct siRNA into colon cancer cells that co-express EpCAM and Her3 Receptors
Silencers target genes that are conditionally essential for cancer cells (synthetic lethal)
Stage
- Components validated and SeekRs designed
- Plan to run in vivo studies to select lead | IND enabling studies in 2022Q3
- IND anticipated in 2023Q3
Clinical Focus
- Phase I focuses on patients with metastatic colon cancer
Strategy & Impact
- Seek breakthrough therapy designation for patients who have progressed on all available therapies
OLI-0102 Anti-Cancer SeekR Program
Multitargeting SeekR™ to trigger synthetic lethality in lung/breast tumors
Lead Candidate: aptTROP2 + siTargetSL + aptHER3
Binders direct siRNA into Lung/Breast cancer cells that co-express TROP2 and Her3 Receptors
Silencers target genes that are conditionally essential for cancer cells (synthetic lethal)
Stage
- Components validated and SeekRs designed
- Plan to run in vivo studies to select lead | IND enabling studies TBD
- IND date TBD
Clinical Focus
- Phase I focuses on patients with metastatic NSCLC and breast cancer
Strategy & Impact
- Seek breakthrough therapy designation for patients who have progressed on all available therapies
OLI-0103 Anti-Cancer SeekR Program
Multitargeting SeekR™ to trigger synthetic lethality in prostate tumors
Lead Candidate: aptTROP2 + siTargetSL + siTargetO aptPSMA
Binders direct siRNA into prostate cancer cells that co-express TROP2 and PSMA Receptors
Silencers target genes that are conditionally essential for cancer cells (synthetic lethal)
Stage
- Components validated and SeekRs designed
- Plan to run in vivo studies to select lead | IND enabling studies in TBD
- IND date TBD
Clinical Focus
- Phase I focuses on patients with metastatic prostate cancer
Strategy & Impact
- Seek breakthrough therapy designation for patients who have progressed on all available therapies
OLI-0201 T-Cell Directed IO Program
Multitargeting SeekR™ T-cell based solid tumor immunotherapy
Lead Candidate: aptPD1 + siTargetX + siTargetY + aptCTLA4
Binders block both PD1 and CTLA4 checkpoints and direct siRNA into T-cells
Silencers block two forms of IO resistance (T-cell exhaustion + TIL toxicity)
Stage
- Components validated and SeekRs designed
- Plan to run in vivo studies to select lead | IND enabling studies in 2022Q3
- IND anticipated in 2023Q3
Clinical Focus
- Phase I focuses patients who progress on antiPD1 antibody therapy
- Evaluation of PD1 and NR4A1 expression & correlation to outcomes
Strategy & Impact
- Develop patient selection strategy
- Seek unmet needs to accelerate approval – breakthrough therapy designation
OLI-0301 Cancer Directed IO Program
Multitargeting SeekR™ cancer cell directed solid tumor IO therapy
Lead Candidate: aptEpCAM + siTargetA + siTargetB + aptEpCAM
Aptamer binders direct siRNA into cancer cells
siRNA silencers block two key targets in cancer cells in order to reverse immune resistance
Stage
- Components validated and SeekRs designed
- Plan to run in vivo studies to select lead | IND enabling studies TBD
- IND date TBD
Clinical Focus
- Phase I focuses patients who progress on antiPD1 antibody therapy
- Evaluation of target expression & correlation to outcomes
Strategy & Impact
- Develop patient selection strategy
- Seek unmet needs to accelerate approval – breakthrough therapy designation
OLI-0401 Endothelial Cell Targeting IO Program
Multitargeting SeekR™ therapeutics to reverse atherosclerosis
Lead Candidate: aptVCAM + anti-miC + anti-mirD + aptICAM
Aptamer binders direct siRNA into endothelial cells
Anti-microRNA oligos inhibit key miRNA involved in the pathogenesis of atherosclerosis
Stage
- Components in development
- To be developed with pharma partner
- IND date TBD
Clinical Focus
- To be developed with pharma partner
- Phase I focuses percutaneous coronary intervention candidates
Strategy & Impact
- To be developed with pharma partner
- Coronary angioplasty and imaging endpoints